Esperion Therapeutics Inc (ESPR)

08:03 AM

Esperion Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

08:03 AM

07:12 AM

What analysts say about Esperion Therapeutics Inc. stockExplosive earning power - Autocar Professional

07:12 AM

Jul 22, 2025

Is Esperion Therapeutics Inc. a good long term investmentAccelerated profit realization - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative

Jul 22, 2025

Jul 22, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewswire

Jul 22, 2025

Jul 22, 2025

What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com

Jul 22, 2025

Jul 15, 2025

How Esperion Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - beatles.ru

Jul 15, 2025

Jul 09, 2025

Esperion settles litigation with Accord Healthcare - MSN

Jul 09, 2025

Jul 08, 2025

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Jul 08, 2025

Jul 08, 2025

Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040 - MarketScreener

Jul 08, 2025

Jul 08, 2025

Esperion Therapeutics Secures Extended NEXLETOL Patent Protection: A Strategic Play for Market Dominance - AInvest

Jul 08, 2025

Jul 08, 2025

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq

Jul 08, 2025

Jul 08, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal - Stock Titan

Jul 08, 2025

Jul 02, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR) - ACCESS Newswire

Jul 02, 2025

Jul 01, 2025

Esperion Appoints Craig Thompson to Board of Directors - GlobeNewswire

Jul 01, 2025

Jul 01, 2025

Esperion Expands Board with New Appointment - TipRanks

Jul 01, 2025

Jun 27, 2025

Dyslipidemia Market is expected to reach US$ 40.33 Billion - openPR.com

Jun 27, 2025

Jun 17, 2025

ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus

Jun 17, 2025

Jun 17, 2025

RFK Racing Teams Up with Esperion for the Wellness Walk at Pocono - Speedway Digest

Jun 17, 2025

Jun 16, 2025

Esperion Therapeutics Soars 19.66% on Positive Clinical Data, Debt Restructuring - AInvest

Jun 16, 2025

Jun 14, 2025

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha

Jun 14, 2025

Jun 13, 2025

Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada

Jun 13, 2025

Jun 12, 2025

ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus

Jun 12, 2025

Jun 11, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025

Jun 10, 2025

Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World

Jun 10, 2025

Jun 09, 2025

Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025

Jun 07, 2025

Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World

Jun 07, 2025

Jun 05, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire

Jun 05, 2025

Jun 05, 2025

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025

Jun 05, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 04, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia

Jun 04, 2025

Jun 03, 2025

ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025

Jun 03, 2025

Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025

Jun 03, 2025

Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa

Jun 03, 2025

Jun 02, 2025

Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com

Jun 02, 2025

Jun 02, 2025

Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks

Jun 02, 2025

Jun 02, 2025

Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus

Jun 02, 2025

Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire

Jun 02, 2025

Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times

Jun 02, 2025

Jun 02, 2025

Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan

Jun 02, 2025

Jun 02, 2025

MarketsMedicine Hat News - FinancialContent

Jun 02, 2025

May 31, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World

May 31, 2025

May 31, 2025

Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 31, 2025

May 31, 2025

Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World

May 31, 2025

May 30, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World

May 30, 2025

May 30, 2025

Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World

May 30, 2025

May 27, 2025

BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 27, 2025